Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
87% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. MDXG: No Debt )
MDXG' s 10-Year Cash to Debt Range
Min: 0   Max: No Debt
Current: No Debt

Equity to Asset 0.84
MDXG's Equity to Asset is ranked higher than
87% of the 443 Companies
in the Global Medical Devices industry.

( Industry Median: 0.64 vs. MDXG: 0.84 )
MDXG' s 10-Year Equity to Asset Range
Min: 0.44   Max: 0.89
Current: 0.84

0.44
0.89
Interest Coverage No Debt
MDXG's Interest Coverage is ranked higher than
95% of the 257 Companies
in the Global Medical Devices industry.

( Industry Median: 234.31 vs. MDXG: No Debt )
MDXG' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 35.21
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 1.07
MDXG's Operating margin (%) is ranked higher than
67% of the 456 Companies
in the Global Medical Devices industry.

( Industry Median: 5.53 vs. MDXG: 1.07 )
MDXG' s 10-Year Operating margin (%) Range
Min: -1334.98   Max: -4.46
Current: 1.07

-1334.98
-4.46
Net-margin (%) 0.99
MDXG's Net-margin (%) is ranked higher than
68% of the 456 Companies
in the Global Medical Devices industry.

( Industry Median: 4.05 vs. MDXG: 0.99 )
MDXG' s 10-Year Net-margin (%) Range
Min: -1447.4   Max: -6.95
Current: 0.99

-1447.4
-6.95
ROE (%) 1.41
MDXG's ROE (%) is ranked higher than
68% of the 440 Companies
in the Global Medical Devices industry.

( Industry Median: 5.22 vs. MDXG: 1.41 )
MDXG' s 10-Year ROE (%) Range
Min: -276.61   Max: -8.79
Current: 1.41

-276.61
-8.79
ROA (%) 1.20
MDXG's ROA (%) is ranked higher than
70% of the 472 Companies
in the Global Medical Devices industry.

( Industry Median: 2.73 vs. MDXG: 1.20 )
MDXG' s 10-Year ROA (%) Range
Min: -557.14   Max: -6.86
Current: 1.2

-557.14
-6.86
ROC (Joel Greenblatt) (%) 5.57
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 470 Companies
in the Global Medical Devices industry.

( Industry Median: 9.36 vs. MDXG: 5.57 )
MDXG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2458.54   Max: -22.77
Current: 5.57

-2458.54
-22.77
Revenue Growth (3Y)(%) 293.60
MDXG's Revenue Growth (3Y)(%) is ranked higher than
100% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. MDXG: 293.60 )
MDXG' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 293.6
Current: 293.6

0
293.6
EBITDA Growth (3Y)(%) -60.30
MDXG's EBITDA Growth (3Y)(%) is ranked higher than
52% of the 305 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. MDXG: -60.30 )
MDXG' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 152
Current: -60.3

0
152
EPS Growth (3Y)(%) -40.50
MDXG's EPS Growth (3Y)(%) is ranked higher than
56% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. MDXG: -40.50 )
MDXG' s 10-Year EPS Growth (3Y)(%) Range
Min: -64   Max: 397.8
Current: -40.5

-64
397.8
» MDXG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MDXG Guru Trades in Q4 2013

Steven Cohen 898,000 sh (New)
Jim Simons 100,350 sh (New)
Caxton Associates 50,000 sh (New)
» More
Q1 2014

MDXG Guru Trades in Q1 2014

Steven Cohen 1,035,000 sh (+15.26%)
Caxton Associates Sold Out
Jim Simons Sold Out
» More
Q2 2014

MDXG Guru Trades in Q2 2014

Jim Simons 179,900 sh (New)
Steven Cohen 906,800 sh (unchged)
» More
Q3 2014

MDXG Guru Trades in Q3 2014

Joel Greenblatt 17,878 sh (New)
Jim Simons 251,000 sh (+39.52%)
Steven Cohen 825,000 sh (-9.02%)
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy$6.28 - $7.44 $ 8.6224%17878
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 1436.70
MDXG's P/E(ttm) is ranked higher than
71% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 88.80 vs. MDXG: 1436.70 )
MDXG' s 10-Year P/E(ttm) Range
Min: 1151.67   Max: 1978.33
Current: 1436.7

1151.67
1978.33
Forward P/E 31.06
MDXG's Forward P/E is ranked higher than
84% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 31.06 )
N/A
PE(NRI) 862.00
MDXG's PE(NRI) is ranked higher than
71% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 84.40 vs. MDXG: 862.00 )
MDXG' s 10-Year PE(NRI) Range
Min: 691   Max: 1187
Current: 862

691
1187
P/B 11.34
MDXG's P/B is ranked higher than
55% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 4.18 vs. MDXG: 11.34 )
MDXG' s 10-Year P/B Range
Min: 5.5   Max: 21.82
Current: 11.34

5.5
21.82
P/S 9.47
MDXG's P/S is ranked higher than
58% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. MDXG: 9.47 )
MDXG' s 10-Year P/S Range
Min: 6.84   Max: 148
Current: 9.47

6.84
148
PFCF 172.40
MDXG's PFCF is ranked higher than
79% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 172.40 )
MDXG' s 10-Year PFCF Range
Min: 138.2   Max: 237.4
Current: 172.4

138.2
237.4
POCF 107.75
MDXG's POCF is ranked higher than
71% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 58.93 vs. MDXG: 107.75 )
MDXG' s 10-Year POCF Range
Min: 86.38   Max: 372
Current: 107.75

86.38
372
EV-to-EBIT 835.95
MDXG's EV-to-EBIT is ranked higher than
70% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 74.50 vs. MDXG: 835.95 )
MDXG' s 10-Year EV-to-EBIT Range
Min: -299.1   Max: 1247
Current: 835.95

-299.1
1247
Current Ratio 5.35
MDXG's Current Ratio is ranked higher than
86% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. MDXG: 5.35 )
MDXG' s 10-Year Current Ratio Range
Min: 0.05   Max: 7.08
Current: 5.35

0.05
7.08
Quick Ratio 5.02
MDXG's Quick Ratio is ranked higher than
89% of the 464 Companies
in the Global Medical Devices industry.

( Industry Median: 1.96 vs. MDXG: 5.02 )
MDXG' s 10-Year Quick Ratio Range
Min: 0.05   Max: 6.7
Current: 5.02

0.05
6.7
Days Inventory 126.03
MDXG's Days Inventory is ranked higher than
77% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 160.07 vs. MDXG: 126.03 )
MDXG' s 10-Year Days Inventory Range
Min: 11.88   Max: 135.08
Current: 126.03

11.88
135.08
Days Sales Outstanding 88.01
MDXG's Days Sales Outstanding is ranked higher than
67% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 79.24 vs. MDXG: 88.01 )
MDXG' s 10-Year Days Sales Outstanding Range
Min: 74.94   Max: 103.26
Current: 88.01

74.94
103.26

Valuation & Return

vs
industry
vs
history
Price/Net Cash 29.73
MDXG's Price/Net Cash is ranked higher than
86% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 29.73 )
MDXG' s 10-Year Price/Net Cash Range
Min: 20.43   Max: 140
Current: 29.73

20.43
140
Price/Net Current Asset Value 17.95
MDXG's Price/Net Current Asset Value is ranked higher than
81% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 17.95 )
MDXG' s 10-Year Price/Net Current Asset Value Range
Min: 13.62   Max: 88.25
Current: 17.95

13.62
88.25
Price/Tangible Book 13.90
MDXG's Price/Tangible Book is ranked higher than
60% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 7.44 vs. MDXG: 13.90 )
MDXG' s 10-Year Price/Tangible Book Range
Min: 10.57   Max: 237.5
Current: 13.9

10.57
237.5
Price/DCF (Projected) 39.18
MDXG's Price/DCF (Projected) is ranked higher than
80% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 39.18 )
MDXG' s 10-Year Price/DCF (Projected) Range
Min: 32.41   Max: 354.5
Current: 39.18

32.41
354.5
Price/Median PS Value 0.76
MDXG's Price/Median PS Value is ranked higher than
88% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. MDXG: 0.76 )
MDXG' s 10-Year Price/Median PS Value Range
Min: 0.59   Max: 11.25
Current: 0.76

0.59
11.25
Price/Graham Number 24.63
MDXG's Price/Graham Number is ranked higher than
73% of the 515 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. MDXG: 24.63 )
MDXG' s 10-Year Price/Graham Number Range
Min: 20.37   Max: 20.37
Current: 24.63

Earnings Yield (Greenblatt) 0.10
MDXG's Earnings Yield (Greenblatt) is ranked higher than
67% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. MDXG: 0.10 )
MDXG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 0.1
Current: 0.1

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
Traded in other countries:MXE.Germany,
MiMedx Group, Inc. was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
MIMEDX GROUP, INC. FRAUD ALERT -- Andrews & Springer LLC Announces That a Securities Fraud Class... Jan 26 2015
Robbins Arroyo LLP Is Investigating the Officers and Directors of MiMedx Group, Inc. (MDXG) on... Jan 22 2015
Lifshitz & Miller Law Firm Announces Investigation of ChannelAdvisor Corp., eHealth, Inc.,... Jan 15 2015
MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts Jan 15 2015
MiMedx Announces over 30 National Account Contracts Jan 15 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jan 12 2015
MiMedx Announces over 30 National Account Contracts Jan 12 2015
MiMedx Exceeds Fourth Quarter And Full Year 2014 Revenue Forecasts Jan 12 2015
Schubert Jonckheer & Kolbe LLP Launches Investigation into Alleged Breaches of Fiduciary Duty by... Jan 09 2015
MiMedx Group, Inc. Investors Encouraged to Contact Securities Law Firm about Investigation into... Jan 08 2015
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of MiMedx Group, Inc.... Jan 06 2015
MIMEDX GROUP, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 06 2015
MiMedx Announces $10 Million Increase to Stock Repurchase Program Jan 06 2015
Investor Alert: Investigation into MiMedx Group Inc. Announced by Holzer & Holzer, LLC Jan 06 2015
MiMedx Group downgraded by Northland Capital Jan 06 2015
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of MiMedx Group, Inc. Jan 05 2015
INVESTOR ALERT: Investigation of MiMedx Group, Inc. Announced by Glancy Binkow & Goldberg LLP Jan 05 2015
INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into MiMedx Group,... Jan 05 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MiMedx Group,... Jan 05 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MeMedx Group,... Jan 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK